Christopher M Black1, Howard Fillit2, Lin Xie3, Xiaohan Hu4, M Furaha Kariburyo3, Baishali M Ambegaonkar1, Onur Baser5,6, Huseyin Yuce7, Rezaul K Khandker1. 1. Merck & Co., Inc., Kenilworth, NJ, USA. 2. The Icahn School of Medicine at Mount Sinai, and the Alzheimer's Drug Discovery Foundation, New York, NY, USA. 3. STATinMED Research, Ann Arbor, MI, USA. 4. University of Southern California, Los Angeles, CA, USA. 5. Department of Surgery, Center for Innovation and Outcomes Research, Columbia University, New York, NY, USA. 6. STATinMED Research, New York, NY, USA. 7. New York City College of Technology (CUNY), New York, NY, USA.
Abstract
BACKGROUND: Current information is scarce regarding comorbid conditions, treatment, survival, institutionalization, and health care utilization for Alzheimer's disease (AD) patients. OBJECTIVES: Compare all-cause mortality, rate of institutionalization, and economic burden between treated and untreated newly-diagnosed AD patients. METHODS: Patients aged 65-100 years with ≥1 primary or ≥2 secondary AD diagnoses (ICD-9-CM:331.0] with continuous medical and pharmacy benefits for ≥12 months pre-index and ≥6 months post-index date (first AD diagnosis date) were identified from Medicare fee-for-service claims 01JAN2011-30JUN2014. Patients with AD treatment claims or AD/AD-related dementia diagnosis during the pre-index period were excluded. Patients were assigned to treated and untreated cohorts based on AD treatment received post-index date. Total 8,995 newly-diagnosed AD patients were identified; 4,037 (44.8%) were assigned to the treated cohort. Time-to-death and institutionalization were assessed using Cox regression. To compare health care costs and utilizations, 1 : 1 propensity score matching (PSM) was used. RESULTS: Untreated patients were older (83.85 versus 81.44 years; p < 0.0001), with more severe comorbidities (mean Charlson comorbidity index: 3.54 versus 3.22; p < 0.0001). After covariate adjustment, treated patients were less likely to die (hazard ratio[HR] = 0.69; p < 0.0001) and were associated with 20% lower risk of institutionalization (HR = 0.801; p = 0.0003). After PSM, treated AD patients were less likely to have hospice visits (3.25% versus 9.45%; p < 0.0001), and incurred lower annual all-cause costs ($25,828 versus $30,110; p = 0.0162). CONCLUSION: After controlling for comorbidities, treated AD patients have better survival, lower institutionalization, and sometimes fewer resource utilizations, suggesting that treatment and improved care management could be beneficial for newly-diagnosed AD patients from economic and clinical perspectives.
BACKGROUND: Current information is scarce regarding comorbid conditions, treatment, survival, institutionalization, and health care utilization for Alzheimer's disease (AD) patients. OBJECTIVES: Compare all-cause mortality, rate of institutionalization, and economic burden between treated and untreated newly-diagnosed ADpatients. METHODS:Patients aged 65-100 years with ≥1 primary or ≥2 secondary AD diagnoses (ICD-9-CM:331.0] with continuous medical and pharmacy benefits for ≥12 months pre-index and ≥6 months post-index date (first AD diagnosis date) were identified from Medicare fee-for-service claims 01JAN2011-30JUN2014. Patients with AD treatment claims or AD/AD-related dementia diagnosis during the pre-index period were excluded. Patients were assigned to treated and untreated cohorts based on AD treatment received post-index date. Total 8,995 newly-diagnosed ADpatients were identified; 4,037 (44.8%) were assigned to the treated cohort. Time-to-death and institutionalization were assessed using Cox regression. To compare health care costs and utilizations, 1 : 1 propensity score matching (PSM) was used. RESULTS: Untreated patients were older (83.85 versus 81.44 years; p < 0.0001), with more severe comorbidities (mean Charlson comorbidity index: 3.54 versus 3.22; p < 0.0001). After covariate adjustment, treated patients were less likely to die (hazard ratio[HR] = 0.69; p < 0.0001) and were associated with 20% lower risk of institutionalization (HR = 0.801; p = 0.0003). After PSM, treated ADpatients were less likely to have hospice visits (3.25% versus 9.45%; p < 0.0001), and incurred lower annual all-cause costs ($25,828 versus $30,110; p = 0.0162). CONCLUSION: After controlling for comorbidities, treated ADpatients have better survival, lower institutionalization, and sometimes fewer resource utilizations, suggesting that treatment and improved care management could be beneficial for newly-diagnosed ADpatients from economic and clinical perspectives.
Authors: Krista R Schaefer; Carolyn Noonan; Michael Mosley; Julia Smith; Donna Galbreath; David Fenn; Renee F Robinson; Spero M Manson Journal: Alzheimers Dement Date: 2019-09-25 Impact factor: 21.566
Authors: Paul Fishman; Norma B Coe; Lindsay White; Paul K Crane; Sungchul Park; Bailey Ingraham; Eric B Larson Journal: Am J Manag Care Date: 2019-08-01 Impact factor: 2.229
Authors: Maria Pisu; Roy C Martin; Liang Shan; Giovanna Pilonieta; Richard E Kennedy; Gabriela Oates; Young-Il Kim; David S Geldmacher Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472
Authors: Lisa Kirk Wiese; Christine L Williams; Debra Hain; David Newman; Christina P Houston; Carolina Kaack; James E Galvin Journal: Geriatr Nurs Date: 2020-10-08 Impact factor: 2.361
Authors: Enrico R Fantoni; Anastasia Chalkidou; John T O' Brien; Gill Farrar; Alexander Hammers Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472